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Abstract: Optic atrophy has often been reported in children with biotinidase deficiency. 
The visual prognosis is usually poor. This report is of a 6-year-old boy with an early onset of 
  biotinidase deficiency who presented with acute profound visual loss in both eyes.   Fundoscopy 
revealed swollen discs in both eyes, and the imaging was consistent with bilateral optic neuritis. 
He was treated with systemic corticosteroid, and commenced on oral biotin. The final visual 
outcome was promising.
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Introduction
Acute optic neuropathy is an inflammatory disorder of the optic nerve. Childhood 
optic neuritis is an uncommon condition which differs from adult onset optic neuritis. 
It is frequently associated with systemic infections such as measles, mumps, chicken 
pox, pertussis, infectious mononucleosis, and immunizations. Less common causes 
include multiple sclerosis or part of a more diffused demyelinating disorder such as 
acute disseminated encephalomyelitis or neuromyelitis optica.
Biotinidase deficiency is an autosomal recessive inborn error of biotin   metabolism. 
Poor vision secondary to optic atrophy in patients with biotinidase deficiency has 
been described in the literature.1–7 This report is on a young boy with biotinidase 
deficiency who suffered an acute attack of optic neuritis in both eyes. Rapid clinical 
diagnosis and prompt management are essential in preventing devastating visual loss 
in this rare entity.
Case report
A 6-year-old Malay boy who had been diagnosed with biotinidase deficiency endured 
sudden reduced vision in both eyes within a period of 5 days. His teacher noted that he 
had difficulty with colors during an art lesson. His mother observed that he bumped 
into objects at home.
Based on further questioning, it was discovered that he had retro-orbital pain 
and a headache. There was no similar history in the past. He had no history of fever, 
symptoms of upper respiratory tract infection, recent vaccination, bleeding tenden-
cies, or trauma.
He was diagnosed with biotinidase deficiency at 18 months of age when he presented 
with generalized impetigo, delayed developmental milestone, and recurrent episodes 
of seizure. His plasma biotin concentration was confirmed as low. His elder brother 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
389
CASE REPORT
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S29048Clinical Ophthalmology 2012:6
and two paternal uncles were also diagnosed with biotinidase 
deficiencies. Both parents had a consanguinity marriage.
He was started on a 6 mg daily dose of oral biotin, 
however the compliance was poor. He was also suffering 
from bronchial asthma with a history of recurrent acute 
exacerbation, and was prescribed a metered-dose-inhaler of 
  salbutamol. There had been no seizure attacks for the past 
3 years and his anticonvulsant treatment was discontinued.
On examination, visual acuity was 1/160 in both eyes. The 
anterior segment examination was unremarkable in both eyes 
except for the presence of a mild relative afferent pupillary 
defect in the right eye. Funduscopy revealed swollen and 
hyperemic optic discs in both eyes (Figure 1A and B). The 
retina was normal in both eyes. Color vision and red desatura-
tion were generally reduced in both eyes. Visual field assess-
ment was not performed as the patient was uncooperative.
The patient was well oriented and afebrile. He was intel-
lectually normal. He had a steady gait. The other cranial nerve 
examinations were normal, and there was no   lymphadenopathy 
elicited. Both lungs were clear, with no sign of exacerbation of 
bronchial asthma. His hair and hearing assessments were normal. 
Examination of the lower limbs revealed numerous scars from 
previous impetigo, healed eczema, and dry scaly skin.
Blood investigations showed normal white cell count. 
There was no evidence of leukocytosis or eosinophilia. 
  Erythrocyte sedimentation rate was raised to 30 mm during 
the first hour. Serology screening for toxoplasmosis and 
  herpes infection was negative. Antinuclear antibody screen-
ing and skin tuberculin tests were also negative.
The biotinidase activity in dried blood spots was less 
than 0.1 pmol/min/µL (normal range: 6.3–9.3 pmol/min/µL). 
Plasma levels of 3-hydroxyisovalerate and 3-hydroxypropi-
onate were increased. Similarly, the urinary levels of organic 
acids 3-hydroxyisovalerate and 3-hydroxypropionate were 
also raised.
Visual evoke potential was delayed bilaterally. Magnetic 
resonance (MR) imaging of orbit was consistent with optic 
neuritis. The brain imaging was normal (Figure 2A and B). 
Cerebrospinal fluid analysis was within normal range for cell 
counts, protein, sugar, and gamma globulin levels.
He was started on intravenous methylprednisolone 
125 mg 6-hourly for 3 days, followed by oral prednisolone 
1 mg/kg daily for 11 days. The dosage was tapered down 
slowly. He was also recommenced on oral biotin 10 mg daily. 
The optic nerve functions were monitored closely. He showed 
remarkable improvement with the above treatment.
His visual acuity improved to 6/7.5 in both eyes after 
1 month. Color vision and red desaturation were subsequently 
improved. Both fundi showed normal and a well-defined margin 
of the optic discs (Figure 1C and D). The urinary organic acid 
profile returned to normal 1 month after oral biotin therapy. 
His case was followed up for 1 year and visual acuity in both 
eyes remained good with no sign of recurrence.
Discussion
Deficiency of biotinidase enzyme causes loss of biocytin 
in urine and progressive depletion of biotin which results 
in multiple carboxylase deficiency. It is characterized by 
neurological and cutaneous manifestations, and metabolic 
abnormalities. Classically, it is presented with hypotonia, 
seizures, ataxia, dermatitis, alopecia, and recurrent infections 
during the first year of life.8 Progressive neurological damage 
such as sensorineural hearing loss, optic atrophy, ataxia, and 
mental retardation has been described in older children.8–10
Salbert et al described 51% ophthalmic abnormalities 
in 78 symptomatic children with biotinidase deficiency.1 
This included 30% infections, 13% optic neuropathies, 13% 
motility disturbances, 4% retinal pigment changes, and 1% 
pupillary findings, while the most common features were 
optic atrophy and keratoconjunctivitis.1
Table 1 summarizes cases of optic neuropathy in children 
with biotinidase deficiency published in PubMed11 from   
1997 to 2011. Our search was made on keywords of “optic 
neuropathy,” “child,” and “biotinidase deficiency”. We 
documented seven patients, and reviewed their age, gender, 
ocular features, funduscopy, systemic features and onset of 
biotinidase deficiency, treatment received, and their final 
visual outcome. They presented with ocular signs at ages 
ranging between 5 and 15 years old. Six of seven patients 
(85.7%) presented with optic atrophy in both eyes, while the 
remaining one patient (14.3%) displayed normal looking 
optic discs bilaterally.2–5,9–10 Unfortunately, the final visual 
outcome was poor in 71.4% (five patients).2–5
In contrast, Puertas et al reported a 12-year-old boy with 
biotinidase deficiency and presented symptoms of acute 
retrobulbar neuritis in both eyes.9 Similarly, our patient also 
exhibited acute papillitis in both eyes. These two patients were 
identified during the acute attack, and they were successfully 
treated with a combination of intravenous corticosteroid and 
oral biotin. Their final visual acuity was satisfactory.
Our patient had poor compliance to biotin therapy. 
His biotinidase activity was confirmed low (less than 
0.1 pmol/min/µL), and this supports the diagnosis of 
biotinidase deficiency. Raised urinary levels of organic 
acids 3-hydroxyisovalerate and 3-hydroxypropionate suggest 
multiple carboxylase deficiencies in our patient.
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Figure 1 (A and B) fundus photographs show bilateral swollen disc on presentation. (C and D) resolved bilateral disc swelling at one month after treatment.
Axial T1  
Axia T1 post gadoliniumA xia T1 post gadolinium
A B
C D
E F
Axial T1 
Figure 2 (A and B) MRI of the optic nerve shows expansion with slight increase signal intensity on T2-weighted image involving both optic nerves (left) and enhancement 
in T1-weighted image post IV contrast. (C–F) MRI of the optic nerve (white arrow) and both optic nerves (white double arrowheads) shows expansion and enhancement 
on T1-weighted image and post gadolinium images.
Abbreviation: MRI, magnetic resonance image.
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Figure 3 (A) Possible mechanism explains retinal ganglion cell apoptosis and acidosis in biotinidase deficiency. (B) Possible mechanism describes neuronal damage.
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Figure 4 (A) Possible mechanism improvement of energy production to retinal ganglion cell and resolved acidosis after biotin therapy in biotinidase deficiency. (B) Possible 
mechanism limits neuronal damage.
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There are possible explanations regarding the occurrence 
of optic neuritis in children with biotinidase deficiency 
(Figure 3A and B).12,13 Decreased amount of biotin causes 
reduction of methylcrotonyl-CoA carboxylase activity. This 
leads to the accumulation of 3-methylcrotonyl-CoA, and sub-
sequently the formation of 3-methylcrotonic acid. This will 
be modified later to 3-hydroxyisovaleric acid.   Accumulation 
and storage of these two acids in the retinal ganglion cells 
directly affects the intracellular metabolism and leads to 
retinal ganglion cells apoptosis.12,13
Due to high energy demand and the long course of 
their axons, retinal ganglion cells are very susceptible to 
intracellular metabolic defect. In biotinidase deficiency, 
the decreased amount of biotin causes a lower activity of 
propionyl-CoA carboxylase. This leads to the accumulation 
of propionyl-CoA which can be converted later into propionic 
acid resulting in acidosis.12,13
In addition to that, propionyl-CoA can be processed 
into methylcitrate by an enzyme in the citric acid cycle. 
  Methylcitrate blocks the normal function of citric acid. This 
causes limited energy production in the retinal ganglion 
cells and subsequently, results in cell apoptosis. The above 
factors may lead to optic neuropathy and consequently result 
in irreversible optic atrophy.12,13
Corticosteroid is the standard modality for treatment 
of optic neuritis. It acts to decrease inflammation by sup-
pressing migration of polymorphonuclear leukocytes and 
reversing increased capillary permeability. The Optic Neu-
ritis   Treatment Trial14 describes the recommended treatment 
for adult onset optic neuritis.15 Our patient tolerated the 
corticosteroid therapy well.
Children with profound biotinidase deficiency have less 
than 10% of mean serum biotinidase enzyme activity, while 
children with partial biotinidase deficiency have 10%–30% 
of mean serum biotinidase enzyme activity. Both profound 
and partial biotinidase deficiency are usually identified by 
newborn screening. Unfortunately, this test is not performed 
routinely in our country.
Optic neuritis is uncommon in children with biotini-
dase deficiency. It is important for ophthalmologists and 
  pediatricians to be aware of this diagnosis when a child with 
biotinidase deficiency presents symptoms of acute visual loss. 
Prompt diagnosis and early treatment is mandatory to avoid 
irreversible visual loss in these children. The combination 
of systemic corticosteroid and biotin treatment seemed an 
effective treatment with our patient.
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